Trilaciclib - G1 Therapeutics
Alternative Names: COSELA; G1T 28; G1T28-1Latest Information Update: 24 Sep 2024
At a glance
- Originator G1 Therapeutics
- Developer Boehringer Ingelheim; G1 Therapeutics; Quantum Leap Healthcare Collaborative; Simcere Pharmaceutical Group
- Class Amines; Antineoplastics; Aza compounds; Chemoprotectants; Cyclohexanes; Ketones; Piperazines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Radioprotectives; Small molecules; Spiro compounds
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Myelosuppression; Small cell lung cancer
- Phase III Colorectal cancer; Triple negative breast cancer
- Phase II Bladder cancer; Breast cancer; Non-small cell lung cancer
- No development reported Cancer
Most Recent Events
- 18 Sep 2024 G1 Therapeutics has been acquired by Pharmacosmos
- 24 Jun 2024 Trilaciclib - G1 Therapeutics is available for licensing as of 24 Jun 2024. https://www.g1therapeutics.com/
- 24 Jun 2024 Efficacy and adverse events data from the phase III PRESERVE 2 trial in Triple negative breast cancer released by G1 Therapeutics